NEW YORK, Feb. 29, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA. The presentation is scheduled for Tuesday, March 8th, 2016 at 10:00 am EST.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
CONTACT: Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Instagram Outage Disrupts Thousands of U.S. Users
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



